Susan A. McDonald

Gastric Stasis in Migraine: More Than Just a Paroxysmal Abnormality During a Migraine Attack

Objective.—The aim of this article is to evaluate gastric motility and emptying in the ictal and interictal period in migraine.

Gastric Stasis Occurs in Spontaneous, Visually Induced, and Interictal Migraine

Objective.— To evaluate and compare gastric motility and emptying during spontaneous migraine to previous observations from induced migraine.

Combination Treatment for Menstrual Migraine and Dysmenorrhea Using Sumatriptan―Naproxen: Two Randomized Controlled Trials

OBJECTIVE: To evaluate the efficacy and tolerability of sumatriptan–naproxen during the mild pain phase of a single menstrual migraine attack associated with dysmenorrhea. METHODS: Two replicate randomized, multicenter, double-blind, placebo-controlled, trials of adults with menstrual migraine and dysmenorrhea were conducted. Participants treated their menstrual migraine attack during the mild pain phase (within 1 hour of onset) with sumatriptan 85 mg and naproxen sodium 500 mg in a single fixed-dose formulation (sumatriptan–naproxen) or placebo. The primary endpoint was 2-hour pain-free response. RESULTS: Sumatriptan–naproxen was statistically superior to placebo in both studies (n=311, Study 1; n=310, Study 2) for 2-hour and, 2- to 24-hour sustained pain-free response, use of headache and menstrual rescue medications, and several nonpain menstrual symptom categories. Two-hour pain-free rates were Study 1, 42% compared with 23%, and Study 2, 52% compared with 22%, P<.001. Two- to 24-hour sustained pain-free rates were Study 1, 29% compared with 18%, P=.022; Study 2, 38% compared with 10%, P<.001. Headache and menstrual medication rates were Study 1, 37% compared with 53%, P=.005; Study 2, 31% compared with 69%, P<.001. Women treated with sumatriptan–naproxen continued to be pain free through 48 hours compared with placebo: Study 1, 26% compared with 17%, P=.040; Study 2, 28% compared with 8%, P<.001. No serious adverse events were reported in either study; nausea and dizziness were the most frequently reported adverse events. CONCLUSION: Sumatriptan–naproxen provided an effective pain-free response at 2 hours, which was maintained up to 48 hours in menstrual migraineurs with dysmenorrhea. Sumatriptan–naproxen was well-tolerated and resulted in decreased rescue medication use and relief of nonpainful menstrual symptoms. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00329459 and NCT00329355 LEVEL OF EVIDENCE: I

Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes.

Objective.—To describe the pain relief, satisfaction, and health‐related quality of life results of moderate or severe migraines treated with a sumatriptan/naproxen sodium combination tablet.

Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine.

Objective.— To reexamine the efficacy of terminating migraine headache by administration of sumatriptan during the visual‐aura phase of the attack.

Changes in Salivary Prostaglandin Levels During Menstrual Migraine With Associated Dysmenorrhea

(Headache 2010;50:844‐851)

Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents.

Objectives.— To evaluate the long‐term safety, tolerability, effectiveness, impact on quality of life, and medication satisfaction of sumatriptan/naproxen sodium in the acute treatment of migraine headache in adolescents.

Clarification of developing and established clinical allodynia and pain-free outcomes

Objective.—The aim of this study was to determine whether clinical indicators of cutaneous allodynia predict the success of migraine therapy with sumatriptan using a brief questionnaire.

Distinct Pharmacokinetic Profile and Safety of a Fixed-Dose Tablet of Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine

(Headache 2010;50:357‐373)

Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan

Aims:  To evaluate treatment satisfaction, efficacy and functional ability of the rapid release formulation of sumatriptan 100 mg tablets (sumatriptan RT 100 mg) in an early intervention paradigm in patients who were dissatisfied with low‐dose sumatriptan and not completely satisfied with their current migraine regimen.